Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Drug Discovery > 2026 Vol. 1 > No. 2 > 100019
Next Article Previous Article
NEWS & BUZZ   Open Access     Cite

[99mTc]Tc-3PRGD2: A first-in-class integrin-targeting SPECT tracer expands the clinical landscape of oncologic nuclear medicine

  • 1.

    Department of Pharmacy, Peking University First Hospital, Xishiku Street, Xicheng District, Beijing 100034, China

  • 2.

    Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China

  • 3.

    State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Xueyuan Road 38, Haidian District, Beijing 100191, China

More Information
The Innovation Drug Discovery  1(2),  https://doi.org/10.59717/j.xinn-drugdisc.2026.100019  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Zhu Z, Song S, Wang X, et al. (2025). Integrin αVβ3-targeted imaging for identification of lung cancer and mapping of lymph-node metastases: A prospective, multicenter, self-controlled phase 3 trial (TRIIL study). J. Clin. Oncol. 43:8017. DOI:10.1200/JCO.2025.43.16_suppl.8017

    View in Article CrossRef Google Scholar

    [2] Ji B, Chen B, Wang T, et al. (2015). 99mTc-3PRGD2 SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer. Eur. J. Nucl. Med. Mol. Imaging 42:1362−1370. DOI:10.1007/s00259-015-3062-1

    View in Article CrossRef Google Scholar

    [3] Lv N, Gao S, Bai L, et al. (2019). Advantages of 99mTc-3PRGD2 SPECT over CT in the preoperative assessment of lymph node metastasis in patients with esophageal cancer. Ann. Nucl. Med. 33:39−46. DOI:10.1007/s12149-018-1300-x

    View in Article CrossRef Google Scholar

    [4] Gao R, Zhang GJ, Wang YB, et al. (2018). Clinical value of 99mTc-3PRGD2 SPECT/CT in differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin level. Sci. Rep. 8:473. DOI:10.1038/s41598-017-19036-9

    View in Article CrossRef Google Scholar

    [5] Fu H, Huang J, Guo W, et al. (2026). Integrin αvβ3-targeted radionuclide therapy with 177Lu-AB-3PRGD2 in multiple advanced metastatic solid tumors: A prospective, single-arm, single-center, investigator-initiated clinical trial. J. Clin. Oncol. 44:3009. DOI:10.1200/JCO.2026.44.16_suppl.3009

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Rong Z., Xiong Q. and Pang X. (2026). [99mTc]Tc-3PRGD2: A first-in-class integrin-targeting SPECT tracer expands the clinical landscape of oncologic nuclear medicine. The Innovation Drug Discovery 1:100019. https://doi.org/10.59717/j.xinn-drugdisc.2026.100019
    Rong Z., Xiong Q. and Pang X. (2026). [99mTc]Tc-3PRGD2: A first-in-class integrin-targeting SPECT tracer expands the clinical landscape of oncologic nuclear medicine. The Innovation Drug Discovery 1:100019. https://doi.org/10.59717/j.xinn-drugdisc.2026.100019

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(475) PDF downloads(81)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.